Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance

William L. Holland, Joseph T. Brozinick, Li Ping Wang, Eric D. Hawkins, Katherine M. Sargent, Yanqi Liu, Krishna Narra, Kyle L. Hoehn, Trina A. Knotts, Angela Siesky, Don H. Nelson, Sotirios K. Karathanasis, Greg K Fontenot, Morris J. Birnbaum, Scott A. Summers

Research output: Contribution to journalArticle

709 Citations (Scopus)

Abstract

Insulin resistance occurs in 20%-25% of the human population, and the condition is a chief component of type 2 diabetes mellitus and a risk factor for cardiovascular disease and certain forms of cancer. Herein, we demonstrate that the sphingolipid ceramide is a common molecular intermediate linking several different pathological metabolic stresses (i.e., glucocorticoids and saturated fats, but not unsaturated fats) to the induction of insulin resistance. Moreover, inhibition of ceramide synthesis markedly improves glucose tolerance and prevents the onset of frank diabetes in obese rodents. Collectively, these data have two important implications. First, they indicate that different fatty acids induce insulin resistance by distinct mechanisms discerned by their reliance on sphingolipid synthesis. Second, they identify enzymes required for ceramide synthesis as therapeutic targets for combating insulin resistance caused by nutrient excess or glucocorticoid therapy.

Original languageEnglish (US)
Pages (from-to)167-179
Number of pages13
JournalCell Metabolism
Volume5
Issue number3
DOIs
StatePublished - Mar 7 2007

Fingerprint

Ceramides
Glucocorticoids
Insulin Resistance
Obesity
Fats
Sphingolipids
Unsaturated Fats
Physiological Stress
Type 2 Diabetes Mellitus
Rodentia
Cardiovascular Diseases
Fatty Acids
Glucose
Food
Enzymes
Therapeutics
Population
Neoplasms

Keywords

  • HUMDISEASE

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Physiology

Cite this

Holland, W. L., Brozinick, J. T., Wang, L. P., Hawkins, E. D., Sargent, K. M., Liu, Y., ... Summers, S. A. (2007). Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance. Cell Metabolism, 5(3), 167-179. https://doi.org/10.1016/j.cmet.2007.01.002

Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance. / Holland, William L.; Brozinick, Joseph T.; Wang, Li Ping; Hawkins, Eric D.; Sargent, Katherine M.; Liu, Yanqi; Narra, Krishna; Hoehn, Kyle L.; Knotts, Trina A.; Siesky, Angela; Nelson, Don H.; Karathanasis, Sotirios K.; Fontenot, Greg K; Birnbaum, Morris J.; Summers, Scott A.

In: Cell Metabolism, Vol. 5, No. 3, 07.03.2007, p. 167-179.

Research output: Contribution to journalArticle

Holland, WL, Brozinick, JT, Wang, LP, Hawkins, ED, Sargent, KM, Liu, Y, Narra, K, Hoehn, KL, Knotts, TA, Siesky, A, Nelson, DH, Karathanasis, SK, Fontenot, GK, Birnbaum, MJ & Summers, SA 2007, 'Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance', Cell Metabolism, vol. 5, no. 3, pp. 167-179. https://doi.org/10.1016/j.cmet.2007.01.002
Holland, William L. ; Brozinick, Joseph T. ; Wang, Li Ping ; Hawkins, Eric D. ; Sargent, Katherine M. ; Liu, Yanqi ; Narra, Krishna ; Hoehn, Kyle L. ; Knotts, Trina A. ; Siesky, Angela ; Nelson, Don H. ; Karathanasis, Sotirios K. ; Fontenot, Greg K ; Birnbaum, Morris J. ; Summers, Scott A. / Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance. In: Cell Metabolism. 2007 ; Vol. 5, No. 3. pp. 167-179.
@article{3d808e5496534fa08d89fd140e3f0e74,
title = "Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance",
abstract = "Insulin resistance occurs in 20{\%}-25{\%} of the human population, and the condition is a chief component of type 2 diabetes mellitus and a risk factor for cardiovascular disease and certain forms of cancer. Herein, we demonstrate that the sphingolipid ceramide is a common molecular intermediate linking several different pathological metabolic stresses (i.e., glucocorticoids and saturated fats, but not unsaturated fats) to the induction of insulin resistance. Moreover, inhibition of ceramide synthesis markedly improves glucose tolerance and prevents the onset of frank diabetes in obese rodents. Collectively, these data have two important implications. First, they indicate that different fatty acids induce insulin resistance by distinct mechanisms discerned by their reliance on sphingolipid synthesis. Second, they identify enzymes required for ceramide synthesis as therapeutic targets for combating insulin resistance caused by nutrient excess or glucocorticoid therapy.",
keywords = "HUMDISEASE",
author = "Holland, {William L.} and Brozinick, {Joseph T.} and Wang, {Li Ping} and Hawkins, {Eric D.} and Sargent, {Katherine M.} and Yanqi Liu and Krishna Narra and Hoehn, {Kyle L.} and Knotts, {Trina A.} and Angela Siesky and Nelson, {Don H.} and Karathanasis, {Sotirios K.} and Greg K Fontenot and Birnbaum, {Morris J.} and Summers, {Scott A.}",
year = "2007",
month = "3",
day = "7",
doi = "10.1016/j.cmet.2007.01.002",
language = "English (US)",
volume = "5",
pages = "167--179",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - Inhibition of Ceramide Synthesis Ameliorates Glucocorticoid-, Saturated-Fat-, and Obesity-Induced Insulin Resistance

AU - Holland, William L.

AU - Brozinick, Joseph T.

AU - Wang, Li Ping

AU - Hawkins, Eric D.

AU - Sargent, Katherine M.

AU - Liu, Yanqi

AU - Narra, Krishna

AU - Hoehn, Kyle L.

AU - Knotts, Trina A.

AU - Siesky, Angela

AU - Nelson, Don H.

AU - Karathanasis, Sotirios K.

AU - Fontenot, Greg K

AU - Birnbaum, Morris J.

AU - Summers, Scott A.

PY - 2007/3/7

Y1 - 2007/3/7

N2 - Insulin resistance occurs in 20%-25% of the human population, and the condition is a chief component of type 2 diabetes mellitus and a risk factor for cardiovascular disease and certain forms of cancer. Herein, we demonstrate that the sphingolipid ceramide is a common molecular intermediate linking several different pathological metabolic stresses (i.e., glucocorticoids and saturated fats, but not unsaturated fats) to the induction of insulin resistance. Moreover, inhibition of ceramide synthesis markedly improves glucose tolerance and prevents the onset of frank diabetes in obese rodents. Collectively, these data have two important implications. First, they indicate that different fatty acids induce insulin resistance by distinct mechanisms discerned by their reliance on sphingolipid synthesis. Second, they identify enzymes required for ceramide synthesis as therapeutic targets for combating insulin resistance caused by nutrient excess or glucocorticoid therapy.

AB - Insulin resistance occurs in 20%-25% of the human population, and the condition is a chief component of type 2 diabetes mellitus and a risk factor for cardiovascular disease and certain forms of cancer. Herein, we demonstrate that the sphingolipid ceramide is a common molecular intermediate linking several different pathological metabolic stresses (i.e., glucocorticoids and saturated fats, but not unsaturated fats) to the induction of insulin resistance. Moreover, inhibition of ceramide synthesis markedly improves glucose tolerance and prevents the onset of frank diabetes in obese rodents. Collectively, these data have two important implications. First, they indicate that different fatty acids induce insulin resistance by distinct mechanisms discerned by their reliance on sphingolipid synthesis. Second, they identify enzymes required for ceramide synthesis as therapeutic targets for combating insulin resistance caused by nutrient excess or glucocorticoid therapy.

KW - HUMDISEASE

UR - http://www.scopus.com/inward/record.url?scp=33847332202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847332202&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2007.01.002

DO - 10.1016/j.cmet.2007.01.002

M3 - Article

C2 - 17339025

AN - SCOPUS:33847332202

VL - 5

SP - 167

EP - 179

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 3

ER -